Dr Bahlis is an Professor of Medicine and Arthur JE Child Chair in Precision Cancer Medicine at the University of Calgary in the divisions of Hematology and Bone Marrow Transplantation, Medical Oncology, a member of the Charbonneau Cancer Research Institute and the Riddell Center for Cancer Immunotherapy. Dr Bahlis also holds a Dr Bahlis received his medical degree in 1995 from St Joseph University – French Faculty of Medicine. He then completed his internal Medicine residency at the State University of New York followed by a Hematology-Oncology fellowship at the University of Miami. Dr Bahlis also completed a postdoctoral fellowship in cancer biology at the University of Miami under the mentorship of Dr Lawrence Boise. Dr Bahlis’ clinical and laboratory research focus on the study of plasma cell dyscrasia, with particular interest in multiple myeloma genomics and immunogenomics, drug resistance and the development of novel therapeutics including cellular therapies. He has received several awards including the ASCO young investigator award, the International Myeloma Society Ken Anderson Basic and Translational Research Award, Cumming School of Medicine’s Cochrane Distinguished Achievement Award and the Telemachus Award for outstanding mentorship. His have received research funding from several agencies including the Multiple Myeloma Research Foundation, Leukemia and Lymphoma Society, International Myeloma Society, Terry Fox Foundation, the Riney Foundation and the Canadian Institute of Health and Research. His research work was published in many peer-reviewed journals including New England Journal of Medicine, Nature Medicine, Cancer Cell, Blood, Blood Cancer Discovery and Journal of Clinical Oncology. Dr Bahlis served on the American Society of Hematology plasma cell dyscrasia scientific committee and is currently serving as an associate editor for the Blood journal.
Bahlis, Nizar
Hematologic Oncology
Associate Professor
Biography
Area of Focus
Multiple Myeloma, Genomics and Immunogenomics, Cellular therapies.
Summary of Research
My research focuses on the study of the deregulated transcriptional and signaling pathways as well as the genomic alterations (next generation sequencing including single cell sequencing) in multiple myeloma and its immune environment with a particular interest in identifying novel therapeutic targets and delineating mechanisms of drugs resistance and immunotherapy escape. To this goal, we have established a myeloma tissue bank and a genomic sequencing unit fully dedicated to the study of the myeloma genome, epigenome and immunome with the goal to delineate molecular vulnerabilities and identify novel therapeutic targets. My clinical research is also centered on the study of multiple myeloma. I have lead and participated in several national and international myeloma clinical trials (investigator initiated, cooperative groups and pharmaceutical sponsored trials), including first in humans (FIH) phase I, as well as phase II, III and IV trials
Area Of Focus
Multiple Myeloma, Genomics and Immunogenomics, Cellular therapies.
Summary Of Research
My research focuses on the study of the deregulated transcriptional and signaling pathways as well as the genomic alterations (next generation sequencing including single cell sequencing) in multiple myeloma and its immune environment with a particular interest in identifying novel therapeutic targets and delineating mechanisms of drugs resistance and immunotherapy escape. To this goal, we have established a myeloma tissue bank and a genomic sequencing unit fully dedicated to the study of the myeloma genome, epigenome and immunome with the goal to delineate molecular vulnerabilities and identify novel therapeutic targets. My clinical research is also centered on the study of multiple myeloma. I have lead and participated in several national and international myeloma clinical trials (investigator initiated, cooperative groups and pharmaceutical sponsored trials), including first in humans (FIH) phase I, as well as phase II, III and IV trials